Literature DB >> 7097123

Metabolism of plasma mevalonate in rats and humans.

R R Kopito, S B Weinstock, L E Freed, D M Murray, H Brunengraber.   

Abstract

A circadian rhythm in plasma mevalonate was identified in human subjects. This variation, over a 5-fold range, is paralleled by a rhythm in urinary excretion. No such diurnal change in plasma mevalonate was observed in schedule-fed, light-cycled rats, despite the presence of a pronounced rhythm in liver HMG-Coa reductase and sterol synthesis. A linear correlation was found between liver HMG-CoA reductase activity and the rate of hepatic sterol synthesis. Sterol synthesis accounted for 59% of the HMG-CoA reductase activity. A 4-fold increase in plasma mevalonate following bilateral nephrectomy did not feed back on liver HMG-CoA reductase. Turnover rates for circulating R- and S-mevalonate were determined by the kinetics of tritiated tracers. S-Mevalonate exhibited first-order kinetics with a T 1/2 of 19 to 23 min, while R-mevalonate kinetics could be resolved into two phases with half-lives of 9 and 42 min. The renal uptake of circulating mevalonate was measured by the initial rate of increase in plasma mevalonate immediately following bilateral nephrectomy; this was confirmed by determination of the renal arterio-venous difference. This value ranges between 500 and 600 pmol/min for a 250-g rat.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7097123

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

1.  Short-term effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor on cholesterol and bile acid synthesis in humans.

Authors:  T Yoshida; A Honda; J Shoda; M Abei; Y Matsuzaki; N Tanaka; H Miyazaki; T Osuga
Journal:  Lipids       Date:  1997-08       Impact factor: 1.880

2.  Metabolism of R- and S-1,3-butanediol in perfused livers from meal-fed and starved rats.

Authors:  S Desrochers; F David; M Garneau; M Jetté; H Brunengraber
Journal:  Biochem J       Date:  1992-07-15       Impact factor: 3.857

3.  Role of the kidneys in the metabolism of plasma mevalonate. Studies in humans and in rhesus monkeys.

Authors:  D J McNamara; E H Ahrens; T S Parker; K Morrissey
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

4.  Contribution of increased HMG-CoA reductase gene expression to hypercholesterolemia in experimental chronic renal failure.

Authors:  Michal Chmielewski; Elzbieta Sucajtys; Julian Swierczynski; Boleslaw Rutkowski; Wojciech Bogusławski
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

5.  Diurnal variation of plasma methyl sterols and cholesterol in the rat: relation to hepatic cholesterol synthesis.

Authors:  T E Strandberg; R S Tilvis; T A Miettinen
Journal:  Lipids       Date:  1984-03       Impact factor: 1.880

6.  In vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase. Studies in normal subjects.

Authors:  H J Harwood; D M Bridge; P W Stacpoole
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

7.  Plasma mevalonate as a measure of cholesterol synthesis in man.

Authors:  T S Parker; D J McNamara; C D Brown; R Kolb; E H Ahrens; A W Alberts; J Tobert; J Chen; P J De Schepper
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.